The role of transcriptomic biomarkers of endometrial receptivity in personalized embryo transfer for patients with repeated implantation failure.
Biomarkers
Endometrial receptivity
Personalized embryo transfer
RNA-Seq
Repeated implantation failure
Window of implantation
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
28 04 2021
28 04 2021
Historique:
received:
08
12
2020
accepted:
16
04
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Window of implantation (WOI) displacement is one of the endometrial origins of embryo implantation failure, especially repeated implantation failure (RIF). An accurate prediction tool for endometrial receptivity (ER) is extraordinarily needed to precisely guide successful embryo implantation. We aimed to establish an RNA-Seq-based endometrial receptivity test (rsERT) tool using transcriptomic biomarkers and to evaluate the benefit of personalized embryo transfer (pET) guided by this tool in patients with RIF. This was a two-phase strategy comprising tool establishment with retrospective data and benefit evaluation with a prospective, nonrandomized controlled trial. In the first phase, rsERT was established by sequencing and analyzing the RNA of endometrial tissues from 50 IVF patients with normal WOI timing. In the second phase, 142 patients with RIF were recruited and grouped by patient self-selection (experimental group, n = 56; control group, n = 86). pET guided by rsERT was performed in the experimental group and conventional ET in the control group. The rsERT, comprising 175 biomarker genes, showed an average accuracy of 98.4% by using tenfold cross-validation. The intrauterine pregnancy rate (IPR) of the experimental group (50.0%) was significantly improved compared to that (23.7%) of the control group (RR, 2.107; 95% CI 1.159 to 3.830; P = 0.017) when transferring day-3 embryos. Although not significantly different, the IPR of the experimental group (63.6%) was still 20 percentage points higher than that (40.7%) of the control group (RR, 1.562; 95% CI 0.898 to 2.718; P = 0.111) when transferring blastocysts. The rsERT was developed to accurately predict the WOI period and significantly improve the pregnancy outcomes of patients with RIF, indicating the clinical potential of rsERT-guided pET. Trial registration Chinese Clinical Trial Registry: ChiCTR-DDD-17013375. Registered 14 November 2017, http://www.chictr.org.cn/index.aspx.
Sections du résumé
BACKGROUND
Window of implantation (WOI) displacement is one of the endometrial origins of embryo implantation failure, especially repeated implantation failure (RIF). An accurate prediction tool for endometrial receptivity (ER) is extraordinarily needed to precisely guide successful embryo implantation. We aimed to establish an RNA-Seq-based endometrial receptivity test (rsERT) tool using transcriptomic biomarkers and to evaluate the benefit of personalized embryo transfer (pET) guided by this tool in patients with RIF.
METHODS
This was a two-phase strategy comprising tool establishment with retrospective data and benefit evaluation with a prospective, nonrandomized controlled trial. In the first phase, rsERT was established by sequencing and analyzing the RNA of endometrial tissues from 50 IVF patients with normal WOI timing. In the second phase, 142 patients with RIF were recruited and grouped by patient self-selection (experimental group, n = 56; control group, n = 86). pET guided by rsERT was performed in the experimental group and conventional ET in the control group.
RESULTS
The rsERT, comprising 175 biomarker genes, showed an average accuracy of 98.4% by using tenfold cross-validation. The intrauterine pregnancy rate (IPR) of the experimental group (50.0%) was significantly improved compared to that (23.7%) of the control group (RR, 2.107; 95% CI 1.159 to 3.830; P = 0.017) when transferring day-3 embryos. Although not significantly different, the IPR of the experimental group (63.6%) was still 20 percentage points higher than that (40.7%) of the control group (RR, 1.562; 95% CI 0.898 to 2.718; P = 0.111) when transferring blastocysts.
CONCLUSIONS
The rsERT was developed to accurately predict the WOI period and significantly improve the pregnancy outcomes of patients with RIF, indicating the clinical potential of rsERT-guided pET. Trial registration Chinese Clinical Trial Registry: ChiCTR-DDD-17013375. Registered 14 November 2017, http://www.chictr.org.cn/index.aspx.
Identifiants
pubmed: 33910562
doi: 10.1186/s12967-021-02837-y
pii: 10.1186/s12967-021-02837-y
pmc: PMC8082865
doi:
Substances chimiques
Biomarkers
0
Banques de données
ChiCTR
['ChiCTR-DDD-17013375']
Types de publication
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
176Références
Int J Dev Biol. 2014;58(2-4):127-37
pubmed: 25023678
Med Sci Monit Basic Res. 2014 Aug 23;20:138-42
pubmed: 25149683
J Clin Endocrinol Metab. 2014 Dec;99(12):E2744-53
pubmed: 25243572
Reprod Biomed Online. 2017 Jul;35(1):28-36
pubmed: 28476486
Fertil Steril. 2011 Sep;96(3):522-9
pubmed: 21880273
Ann N Y Acad Sci. 1986;476:36-42
pubmed: 3541745
Hum Reprod. 2011 Jun;26(6):1270-83
pubmed: 21502182
Hum Reprod. 1999 Sep;14(9):2345-9
pubmed: 10469708
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Reprod Biol Endocrinol. 2019 Sep 5;17(1):74
pubmed: 31488148
Hum Reprod Update. 2019 Mar 1;25(2):202-223
pubmed: 30624659
Hum Reprod. 2018 Apr 1;33(4):626-635
pubmed: 29452422
Ann N Y Acad Sci. 2004 Dec;1034:1-18
pubmed: 15731295
Cold Spring Harb Perspect Med. 2015 Mar 27;5(7):a022996
pubmed: 25818663
Fertil Steril. 2019 Oct;112(4 Suppl1):e93-e115
pubmed: 31623748
Reprod Biomed Online. 2014 Sep;29(3):291-8
pubmed: 25070912
Bioinformatics. 2012 Jun 1;28(11):1530-2
pubmed: 22539670
Reprod Biomed Online. 2020 Sep;41(3):402-415
pubmed: 32723696
Mol Hum Reprod. 2010 Mar;16(3):178-87
pubmed: 19933690
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Hum Reprod. 1998 Mar;13(3):720-3
pubmed: 9572441
Reprod Biol Endocrinol. 2012 Nov 28;10:100
pubmed: 23190428
Fertil Steril. 2017 Sep;108(3):513-517.e2
pubmed: 28807395
Hum Reprod. 2014 Feb;29(2):279-85
pubmed: 24277748
Fertil Steril. 2011 Jan;95(1):50-60, 60.e1-15
pubmed: 20619403
Fertil Steril. 2004 May;81(5):1333-43
pubmed: 15136099
Hum Reprod Update. 2009 Mar-Apr;15(2):229-36
pubmed: 18997181
J Assist Reprod Genet. 2018 Apr;35(4):683-692
pubmed: 29327111
Hum Reprod. 2014 Jun;29(6):1244-7
pubmed: 24737781
Hum Reprod Update. 2014 Jan-Feb;20(1):12-28
pubmed: 24082038
Fertil Res Pract. 2019 Aug 5;5:9
pubmed: 31396393
Hum Reprod. 2014 Jun;29(6):1238-43
pubmed: 24664129
Hum Reprod Update. 2015 Jan-Feb;21(1):13-38
pubmed: 25155826
Fertil Steril. 2013 Feb;99(2):508-17
pubmed: 23102856
Fertil Steril. 2013 Mar 15;99(4):1078-85
pubmed: 23312228
J Assist Reprod Genet. 2016 Nov;33(11):1419-1430
pubmed: 27480540
Reprod Biol Endocrinol. 2012 Dec 07;10:106
pubmed: 23216986
Reprod Biomed Online. 2014 Apr;28(4):409-23
pubmed: 24581986
Hum Reprod. 2017 Sep 1;32(9):1786-1801
pubmed: 29117321
Hum Reprod Update. 2005 Nov-Dec;11(6):613-30
pubmed: 16006437
Sci Rep. 2017 Aug 30;7(1):10077
pubmed: 28855728
N Engl J Med. 2001 Nov 8;345(19):1400-8
pubmed: 11794174
Fertil Steril. 2013 Sep;100(3):818-24
pubmed: 23756099
Placenta. 2003 Oct;24 Suppl B:S39-47
pubmed: 14559029
Hum Reprod Update. 2007 Jan-Feb;13(1):77-86
pubmed: 16960016
Fertil Steril. 1992 Sep;58(3):537-42
pubmed: 1521649
Fertil Steril. 2019 Oct;112(4 Suppl1):e81-e84
pubmed: 31623746
N Engl J Med. 1999 Jun 10;340(23):1796-9
pubmed: 10362823
Reprod Med Biol. 2017 Jun 27;16(3):290-296
pubmed: 29259480